Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).…
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).…
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug…
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering…
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
Hengrui Pharma has agreed with US-based Braveheart Bio, which specialises in cardiovascular diseases, granting it an exclusive licence for its…
Novartis has secured a licensing agreement with China-based Argo Biopharma just after signing a contract with Arrowhead, marking two small…
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met its…
Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made…
Medera and its subsidiary Novoheart have collaborated with scientists at the University of California San Diego School of Medicine and…